XML 24 R7.htm IDEA: XBRL DOCUMENT v3.8.0.1
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Millions
 9 Months Ended
Oct. 01, 2017
Oct. 02, 2016
Operating Activities    
Net income before allocation to noncontrolling interests [1],[2],[3],[4],[5] $ 9,066 $ 6,465
Adjustments to reconcile net income before allocation to noncontrolling interests to net cash provided by operating activities:    
Depreciation and amortization [5] 4,695 4,208
Asset write-offs and impairments [5] 326 1,146
Loss on sale of HIS net assets [5],[6] 52 1,422
Deferred taxes from continuing operations [5] 241 (1,335)
Share-based compensation expense [5] 595 532
Benefit plan contributions in excess of expense [5] (1,042) (775)
Other adjustments, net [5] (561) 68
Other changes in assets and liabilities, net of acquisitions and divestitures [1],[5] (3,644) (1,582)
Net cash provided by operating activities [1],[5] 9,728 10,151
Investing Activities    
Purchases of property, plant and equipment [5] (1,256) (1,134)
Purchases of short-term investments [5] (6,469) (15,170)
Proceeds from redemptions/sales of short-term investments [5] 5,783 20,685
Net proceeds from redemptions/sales of short-term investments with original maturities of three months or less [5] 2,758 6,485
Purchases of long-term investments [5] (2,526) (4,771)
Proceeds from redemptions/sales of long-term investments [5] 2,417 6,915
Acquisitions of businesses, net of cash acquired [5] (1,000) (17,679)
Acquisitions of intangible assets [5] (188) (96)
Other investing activities, net [5] 519 60
Net cash provided by/(used in) investing activities [5] 38 (4,704)
Financing Activities    
Proceeds from short-term borrowings [5] 7,003 6,397
Principal payments on short-term borrowings [5] (7,691) (3,321)
Net proceeds from/(payments on) short-term borrowings with original maturities of three months or less [5] 555 (963)
Proceeds from issuance of long-term debt [5] 5,273 5,031
Principal payments on long-term debt [5] (4,474) (4,317)
Purchases of common stock [5] (5,000) (5,000)
Cash dividends paid [5] (5,750) (5,496)
Proceeds from exercise of stock options [5] 656 946
Other financing activities, net [1],[5] (223) (192)
Net cash used in financing activities [1],[5] (9,650) (6,915)
Effect of exchange-rate changes on cash and cash equivalents [5] 67 (79)
Net increase/(decrease) in cash and cash equivalents [5] 184 (1,547)
Cash and cash equivalents, beginning [5] 2,595 [7] 3,641
Cash and cash equivalents, end [5] 2,779 [7] 2,094
Non-cash transactions:    
Receipt of ICU Medical common stock [5],[8] 428 0
Promissory note from ICU Medical [5],[8] 75 0
Cash paid (received) during the period for:    
Income taxes [5] 1,424 1,430
Interest [5] 1,101 1,177
Interest rate hedges [5] $ (183) $ (356)
[1] Amounts for the three and nine months ended October 2, 2016 have been revised from previously reported amounts to reflect the adoption of a new accounting standard in the fourth quarter of 2016, as of January 1, 2016. For additional information, see Note 1B. Basis of Presentation and Significant Accounting Policies: Adoption of New Accounting Standards.
[2] Amounts for the three and nine months ended October 2, 2016 have been revised from previously reported amounts to reflect the adoption of a new accounting standard in the fourth quarter of 2016, as of January 1, 2016. For additional information, see Note 1B. Basis of Presentation and Significant Accounting Policies––Adoption of New Accounting Standards.
[3] Amounts may not add due to rounding.
[4] Amounts may not add due to rounding.
[5] Amounts may not add due to rounding.
[6] In the third quarter and first nine months of 2017, represents adjustments to amounts previously recorded to write down the HIS net assets to fair value less costs to sell related to the sale of HIS net assets to ICU Medical. In the third quarter and first nine months of 2016, represents a charge related to the write-down of the HIS net assets to fair value less estimated costs to sell.
[7] Amounts may not add due to rounding.
[8] In connection with the sale of HIS net assets to ICU Medical, on February 3, 2017, Pfizer received 3.2 million newly issued shares of ICU Medical common stock initially valued at $428 million and a promissory note in the amount of $75 million. For additional information, see Note 2B. Acquisitions, Sale of Hospira Infusion Systems Net Assets, Collaborative Arrangement and Equity-Method Investments: Sale of Hospira Infusion Systems Net Assets.